Venus Remedies Limited

Venus Remedies Limited (VENUSREM) is a micro-cap Healthcare company valued at ₹2,195 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Venus Remedies Limited last traded at ₹1,577, modestly up 0.17% on the day.

Recent developments

On 2026-08-07, the company announced a dividend of ₹10.00 per share, ex-date. Foreign institutional holding increased by 0.12 percentage points to 2.92%, while domestic institutional holding fell by 0.31 percentage points to 0.89%. Promoter holding remained at 41.76%.

Financial performance

The company's business has improved significantly, with annual revenue rising 20.3% and net profit surging 128.4%. The latest quarter saw revenue and net profit jump 30.6% and 129.7% respectively compared to the same quarter a year earlier. Net profit margin expanded 6.3 percentage points to 13.4%, while return on capital employed remained at 20.2%.

Valuation multiples

The stock trades at 20.5 times earnings, a discount to the Healthcare median of 32.0, 3.28 times book value. It yields 0.6%.

Things to watch

The company's return on equity is 0.0%, which is a concern. The stock is 12.1% below its 52-week high. The latest quarter's return on equity remains at 0.0%, indicating potential issues with capital efficiency.

Where it stands

The company has delivered strong growth in both revenue and net profit, with the latest quarter showing significant year-over-year improvements. The stock is currently 12.1% below its 52-week high, and return on equity remains at 0.0%. The most recent figure is the latest quarter net profit of ₹23 crore.

Summarised by DocStoX's model on 2026-10-04 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.